<DOC>
	<DOCNO>NCT02166489</DOCNO>
	<brief_summary>This study design provide confirmation safety mesenchymal stem cell ( MSCs ) therapy chronic renal failure due autosomal dominant polycystic kidney disease ( ADPKD ) .</brief_summary>
	<brief_title>Mesenchymal Stem Cells Transplantation Patients With Chronic Renal Failure Due Polycystic Kidney Disease</brief_title>
	<detailed_description>The investigator assess 18-month safety potential efficacy autologous MSCs therapy ADPKD . A total 6 patient ADPKD IV injection high dose 2Ã—106 autologous mesenchymal stem cell / kg weight , derive biopsy bone marrow . Assessments make 1 , 3 , 6 , 12 18 month cell injection . Changes GFR rate evaluate scan isotope .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<criteria>Male Female ADPKD symptom ADPKD confirm sonography genetic test Patient 's age 18 60 year GFR GFR 2560 mL/min/1.73 m2 Ability understand willingness sign consent Pregnancy breastfeeding Associated Cardiovascular disease Diabetes require medical intervention Other systemic disease involve kidney , cancer , autoimmune disease , blood disease , liver disease , etc . Hospitalization due illness last two month Life expectancy less two year Any allergy ingredient use cell culture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>autologous mesenchymal stem cell</keyword>
	<keyword>polycystic kidney disease</keyword>
	<keyword>intravenous injection</keyword>
	<keyword>CRF</keyword>
</DOC>